Stockscreener 앱 받기
29.52
0.37%
-0.11
시간 외 거래:
29.52
전일 마감가:
$29.63
열려 있는:
$29.15
하루 거래량:
715.57K
Relative Volume:
1.60
시가총액:
$535.83M
수익:
$116.88M
순이익/손실:
$-25.09M
주가수익비율:
-210.86
EPS:
-0.14
순현금흐름:
$-20.74M
1주 성능:
-17.33%
1개월 성능:
-11.14%
6개월 성능:
-28.59%
1년 성능:
+45.49%
1일 변동 폭
$28.01
$30.14
1주일 범위
$28.01
$36.57
52주 변동 폭
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
29.52 | 537.82M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Brokers Offer Predictions for RIGL Q1 Earnings - MarketBeat
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty - TipRanks
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives - simplywall.st
Rigel Pharmaceuticals (RIGL) Projects Revenue Decline for 2026 - GuruFocus
Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $71 - 富途牛牛
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and Strategic Growth Initiatives - GuruFocus
Rigel Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress - Yahoo Finance
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect - AlphaStreet News
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Rigel’s Q4 2025 shows robust growth - Investing.com Australia
Earnings call transcript: Rigel’s Q4 2025 shows robust growth By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RIGL) 2026-03-03 - Seeking Alpha
RIGL: Record sales and net income in 2025, with strong growth outlook and pipeline progress for 2026 - TradingView
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates - Bitget
Rigel Pharma (RIGL) Earnings Call Transcript - Nasdaq
Rigel Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Rigel Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rigel Pharmaceuticals Q4 Earnings, Revenue Rise; 2026 Revenue Outlook Set - marketscreener.com
Rigel Pharmaceuticals (RIGL) Projects FY26 Revenue Growth - GuruFocus
Earnings Summary: Rigel Pharmaceuticals Q4 - Benzinga
Rigel Pharmaceuticals (NASDAQ:RIGL) Announces Earnings Results - MarketBeat
RIGL: Record 2025 revenue and net income, with 2026 outlook for continued growth and pipeline progress - TradingView
Rigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20 - TipRanks
Rigel (NASDAQ: RIGL) boosts blood cancer drug sales and advances pipeline - Stock Titan
Rigel: Q4 Earnings Snapshot - marketscreener.com
RIGL: Record 2025 revenue and net income, strong product growth, and positive 2026 outlook - TradingView
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - marketscreener.com
RIGL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rigel Pharmaceuticals (RIGL) Set to Announce Q4 Earnings - GuruFocus
A Preview Of Rigel Pharmaceuticals's Earnings - Benzinga
(RIGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Implied Volatility Surging for Rigel Pharmaceuticals Stock Options - TradingView
RIGL.O Technical Analysis & Stock Price Forecast - Intellectia AI
Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis: Unpacking a 49% Potential Upside for Investors - DirectorsTalk Interviews
Rigel Pharmaceuticals Options See Significant Rise in Implied Volatility - Bitget
Walter Moos Sells 4,000 Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - MarketBeat
Rigel (RIGL) director Moos exercises options and sells 4,000 shares - Stock Titan
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? - Finviz
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? - TradingView
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update - The AI Journal
Rigel Pharmaceuticals (RIGL) Projected to Post Earnings on Tuesday - MarketBeat
Will Tavalisse continue to drive Rigel Pharmaceuticals' growth in 2026? - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Upgraded at Zacks Research - Defense World
How interest rate cuts could boost Rigel Pharmaceuticals Inc. stock2025 Analyst Calls & Weekly Top Performers Watchlists - mfd.ru
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):